https://www.yiliao.com/index.php?action=history&feed=atom&title=EGFR%E7%AA%81%E5%8F%98
EGFR突变 - 版本历史
2026-04-19T05:31:13Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=EGFR%E7%AA%81%E5%8F%98&diff=314696&oldid=prev
223.160.138.164：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-16T06:57:20Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[EGFR突变]]</strong>（<strong>[[EGFR Mutation]]</strong>）是指<strong>[[表皮生长因子受体]]</strong>（[[EGFR]]，又称[[ERBB1]]）基因发生的功能获得性突变。这种突变会导致受体胞内激酶结构域的持续性、非配体依赖性激活，进而驱动细胞的失控性增殖、侵袭和抗凋亡。[[EGFR突变]]是<strong>[[非小细胞肺癌]]</strong>（[[NSCLC]]）中最重要的驱动基因变异之一，在亚洲人群腺癌中的发生率高达40%-50%。临床上，[[EGFR突变]]常被称为“<strong>[[黄金突变]]</strong>”，因其对<strong>[[EGFR-TKI]]</strong>（酪氨酸激酶抑制剂）具有极高的响应率。随着2026年第四代[[TKI]]的临床应用，[[EGFR突变]]肺癌的管理已进入“全病程精准慢病化”时代。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #ffffff 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[EGFR]]突变</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">EGFR Mutation / ERBB1 · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">染色体定位：7p11.2</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1956([[EGFR]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3236</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P00533</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">常见位点</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[19del]] / [[L858R]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">蛋白分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">175 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">突变频率</th><br />
<td style="padding: 12px; color: #0f172a;">~50%(亚洲腺癌)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：信号通路的“脱缰”激活</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
正常状态下，[[EGFR]]需与配体（如[[EGF]]）结合发生二聚化。而致病性[[EGFR突变]]改变了其激酶结构域的构象：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>自发二聚化：</strong>突变（特别是[[19外显子缺失]]和[[21外显子L858R]]）使受体处于一种“开放型”活性构象，导致即使在没有配体的情况下也会发生[[自磷酸化]]。</li><br />
<li style="margin-bottom: 12px;"><strong>下游级联放大：</strong>激活的[[EGFR]]持续刺激<strong>[[RAS/MAPK]]</strong>、<strong>[[PI3K/AKT/mTOR]]</strong>及<strong>[[STAT]]</strong>通路。这些通路通过调控基因转录，维持细胞的恶性表型。</li><br />
<li style="margin-bottom: 12px;"><strong>ATP亲和力改变：</strong>某些耐药突变（如[[T790M]]）通过改变[[ATP]]结合口袋的亲和力，竞争性地排除第一代靶向药物，这是肿瘤逃逸的核心逻辑。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床评价矩阵：突变类型与用药指南</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">突变分类</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">分子特征</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">推荐治疗方案 (2026)</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">经典突变</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[Exon 19 del]] / [[L858R]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">首选[[奥希替尼]]或[[阿美替尼]]；联合[[抗血管药物]]（如[[贝伐珠单抗]]）。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">获得性耐药突变</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[T790M]] / [[C797S]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">针对[[C797S]]选用第四代[[EGFR-TKI]]（如[[BLU-945]]/[[BPI-361186]]）。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">罕见/难治突变</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[Exon 20 ins]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">选用[[莫博赛替尼]]、[[埃万妥单抗]](双抗)或[[伏美替尼]]高剂量方案。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">联合变异</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[EGFR]] + [[MET扩增]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[三代TKI]]联合[[MET抑制剂]]（如[[赛沃替尼]]/[[卡马替尼]]）。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：从精准打击到动态监控</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[EGFR突变]]的现代治疗强调“全程管理”和“预防性拦截”：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>一线前移：</strong>2026年共识明确，无论是否存在[[T790M]]，三代[[TKI]]（如[[奥希替尼]]）均推荐作为一线标准，因其能显著降低[[脑转移]]风险并延长[[PFS]]。</li><br />
<li style="margin-bottom: 12px;"><strong>MRD动态监测：</strong>利用[[液体活检]]技术（[[ctDNA]]）监测治疗过程中的[[微小残留病]]。MRD转阳早于影像学进展，可指导早期干预。</li><br />
<li style="margin-bottom: 12px;"><strong>ADC药物介入：</strong>对于多线[[TKI]]耐药后的患者，靶向[[HER3]]或[[EGFR]]的<strong>[[ADC药物]]</strong>（如[[Patritumab Deruxtecan]]）已成为克服耐药的新基石。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[奥希替尼]]：</strong>第三代不可逆[[TKI]]，目前[[EGFR]]阳性[[NSCLC]]的一线金标准。</li><br />
<li style="margin-bottom: 8px;"><strong>[[C797S]]：</strong>三代药耐药后的核心突变位点，是四代药研发的主攻方向。</li><br />
<li style="margin-bottom: 8px;"><strong>[[MET旁路激活]]：</strong>[[EGFR]]通路被抑制后肿瘤最常用的逃逸手段之一。</li><br />
<li style="margin-bottom: 8px;"><strong>[[液体活检]]：</strong>通过血液检测 $EGFR$ 突变丰度的非侵入性技术。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Mok TS, et al. (2009).</strong> <em>Gefitinib or chemotherapy in non-small-cell lung cancer and the activating mutations of the EGFR.</em> <strong>[[The New England Journal of Medicine]]</strong>. 361:947-957.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：IPASS研究奠定了EGFR检测作为肺癌精准治疗前提的基础地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Soria JY, et al. (2018).</strong> <em>Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.</em> <strong>[[NEJM]]</strong>. 378:113-125.<br><br />
<span style="color: #475569;">[核心价值]：FLAURA研究确立了三代TKI的一线霸主地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Mok TS, et al. (2017).</strong> <em>Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.</em> <strong>[[NEJM]]</strong>. 376:629-640.<br><br />
<span style="color: #475569;">[临床意义]：AURA3研究开启了针对耐药突变精准治疗的新阶段。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[EGFR突变]] (Mutation) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联因子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[ERBB1]]•[[KRAS]]•[[MET扩增]]•[[T790M]]•[[C797S]]•[[PI3K]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[吉非替尼]]•[[厄洛替尼]]•[[阿法替尼]]•[[奥希替尼]]•[[伏美替尼]]•[[阿美替尼]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[AstraZeneca]]•[[Hansoh]]•[[Allist]]•[[NCCN]]•[[FDA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">前沿研究</td><br />
<td style="padding: 10px 15px; color: #334155;">[[第四代EGFR抑制剂联合方案]]•[[ADC药物克服TKI耐药]]•[[基于双抗的EGFR/MET封锁策略]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.164